Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02767362 · ClinicalTrials.gov registry record · Early Phase 1

A Pre-Op Window Study Evaluating Anti-Proliferative Effects of Atorvastatin on the Endometrium

A Early Phase 1 study of Endometrial Cancer, sponsored by UNC Lineberger Comprehensive Cancer Center.

Completed
Registry status
Early Phase 1
Development phase
24
Enrollment target
1
Study location

NCT02767362 is a Early Phase 1 study of Endometrial Cancer that has completed, run by UNC Lineberger Comprehensive Cancer Center. The registered enrollment target is 24 participants, below the 524-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02767362, a Early Phase 1 study of Endometrial Cancer, has completed, sponsored by UNC Lineberger Comprehensive Cancer Center.

COMPLETED
Registry status
Early Phase 1
Development phase
24 participants
Enrollment target
1
Study location

Study Summary

This is a preoperative window, phase 0 study of short-term atorvastatin treatment in obese women who are to undergo surgical staging for endometrial cancer.

Conditions Studied

Interventions

  • DRUG Atorvastatin

Study Locations (1)

North Carolina

  • University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center - Chapel Hill

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2015-11
Est. Completion 2019-09-26
Phase Early Phase 1

What the Registry Record Tells You About NCT02767362

The ClinicalTrials.gov registry entry for NCT02767362 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 524-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (95% lower). The listed sponsor is UNC Lineberger Comprehensive Cancer Center, which has 366 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Endometrial Cancer appearing as the primary indexed condition, and to 1 intervention - of which Atorvastatin is the first listed.

NCT02767362 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT02767362 about?

NCT02767362 is a clinical study titled "A Pre-Op Window Study Evaluating Anti-Proliferative Effects of Atorvastatin on the Endometrium". This is a preoperative window, phase 0 study of short-term atorvastatin treatment in obese women who are to undergo surgical staging for endometrial cancer.

What is the current status of trial NCT02767362?

This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 24 participants. The study started on 2015-11. Estimated completion is 2019-09-26.

What conditions does trial NCT02767362 study?

This clinical trial studies the following conditions: Endometrial Cancer.

What interventions are being tested in trial NCT02767362?

The interventions under investigation include: Atorvastatin (DRUG).

Who is sponsoring clinical trial NCT02767362?

This trial is sponsored by UNC Lineberger Comprehensive Cancer Center, which has 366 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02767362 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Endometrial Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.